Showing results (201-210 of 211) with videos related to
Sort By:
Pageof 22
Journal of Hepatology|October 5, 2024
Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infectionChen-Hua Liu, Pin-Nan Cheng, Yu-Jen Fang, et al.Alimentary Pharmacology & Therapeutics|February 21, 2025
Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral-Induced Cure of Hepatitis C Virus InfectionYu-Ping Chang, Ji-Yuh Lee, Chi-Yi Chen, et al.International Journal of Environmental Research and Public Health|July 27, 2022
Comparing the Psychometric Properties among Three Versions of the UCLA Loneliness Scale in Individuals with Schizophrenia or Schizoaffective DisorderChung-Ying Lin, Ching-Shu Tsai, Cian-Ruei Jian, et al.Journal of Medical Virology|May 15, 2024
Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving fixed-dose pangenotypic direct-acting antiviralsChen-Hua Liu, Yu-Ping Chang, Ji-Yuh Lee, et al.Journal of Gastroenterology|April 13, 2024
Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antiviralsChen-Hua Liu, Yu-Ping Chang, Yu-Jen Fang, et al.Journal of Gastroenterology and Hepatology|November 14, 2025
Predictive Value of Serum Mac-2 Binding Protein Glycosylation Isomer for Hepatic Fibrosis in Hepatitis C Virus-Infected Patients With Metabolic Dysfunction-Associated Steatotic Liver DiseaseYun-Chu Chen, Yu-Ping Chang, Ji-Yuh Lee, et al.Journal of Medical Virology|January 15, 2026
Effect of Glycated Hemoglobin Levels on Serum Mac-2 Binding Protein Glycosylation Isomer in the Diagnosis of Hepatitis C-Virus Related Hepatic FibrosisYu-Ping Chang, Yun-Chu Chen, Ji-Yuh Lee, et al.BMC Cancer|November 9, 2016
Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitorsYu-Mu Chen, Chien-Hao Lai, Kun-Ming Rau, et al.Lung Cancer (Amsterdam, Netherlands)|July 10, 2016
Advanced non-Small cell lung cancer patients at the extremes of age in the era of epidermal growth factor receptor tyrosine kinase inhibitorsYu-Mu Chen, Chien-Hao Lai, Kun-Ming Rau, et al.Gut|January 20, 2026
Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver diseaseYu-Ping Chang, Yun-Chu Chen, Pin-Nan Cheng, et al.Pageof 22